BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34417810)

  • 1. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
    Winkelman JW
    Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
    Bayard S; Langenier MC; Dauvilliers Y
    Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.
    Sun Y; van Valkenhoef G; Morel T
    Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restless legs syndrome: differential diagnosis and management with pramipexole.
    Brindani F; Vitetta F; Gemignani F
    Clin Interv Aging; 2009; 4():305-13. PubMed ID: 19750232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restless legs syndrome: clinical presentation diagnosis and treatment.
    Wijemanne S; Jankovic J
    Sleep Med; 2015 Jun; 16(6):678-90. PubMed ID: 25979181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
    Pourcher E; Rémillard S; Cohen H
    J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation in patients with restless legs syndrome receiving pramipexole therapy: a retrospective study in a single center from China.
    Wang T; Ying M; Zhao R; Zhu D; Zhang L
    Sleep Breath; 2022 Mar; 26(1):373-380. PubMed ID: 33864178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome.
    Kim J; Hartzema AG
    Sleep Med; 2018 Apr; 44():45-52. PubMed ID: 29530369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series.
    Dostal M; Weber-Schoendorfer C; Sobesky J; Schaefer C
    Eur J Neurol; 2013 Sep; 20(9):1241-6. PubMed ID: 23083216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gambling addiction as a side effect of low dose pramipexole in the treatment of restless legs syndrome].
    Lindström ES; Ibsen JD; Skovbølling SL
    Ugeskr Laeger; 2022 Jun; 184(24):. PubMed ID: 35703072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment initiation and utilization patterns of pharmacotherapies for early-onset idiopathic restless legs syndrome.
    Costales B; Vouri SM; Brown JD; Setlow B; Goodin AJ
    Sleep Med; 2022 Aug; 96():70-78. PubMed ID: 35605349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).
    Winkelman JW; Johnston L
    Sleep Med; 2004 Jan; 5(1):9-14. PubMed ID: 14725821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer dopamine agonists in the treatment of restless legs syndrome.
    Weimerskirch PR; Ernst ME
    Ann Pharmacother; 2001 May; 35(5):627-30. PubMed ID: 11346069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
    Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Severe Refractory and Augmented Restless Legs Syndrome.
    Winkelman JW
    Chest; 2022 Sep; 162(3):693-700. PubMed ID: 35609673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole induced psychosis in a patient with restless legs syndrome.
    Signorelli MS; Battaglia E; Costanzo MC; Cannavò D
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24049088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with pramipexole in the treatment of restless legs syndrome.
    Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole in the management of restless legs syndrome: an extended study.
    Silber MH; Girish M; Izurieta R
    Sleep; 2003 Nov; 26(7):819-21. PubMed ID: 14655914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.